Alzheimer's drug from Eisai and Biogen rejected in Europe
EU regulator cites safety concerns, small benefit
Eisai, Biogen to seek re-examination of decision
The drug's launch in the U.S. has been slow
Biogen shares fall 7%, rival Lilly slips 1%
Adds Lilly and analyst comments, paragraph 21-22
By Manas Mishra and Puyaan Singh
July 26 (Reuters) -The European Union's drugs regulator has rejected Eisai 4523.T and Biogen's BIIB.O Leqembi treatment for early Alzheimer's disease, saying the risk of serious brain swelling did not outweigh its small impact on slowing cognitive decline.
The decision is a blow to the companies as the drug faces slow take-up in the U.S. and underscores the complexities tied to a new class of drugs that have benefited early-stage patients, but could cause rare and serious side effects.
Following the rejection, Biogen's shares fell about 7% in U.S. trading, while rival Eli Lilly LLY.N, which makes a similar drug, slipped 1%.
Eisai and Biogen said they will seek re-examination of the recommendation, but did not disclose what information they would provide the regulator.
The therapy, also known as lecanemab, is approved in the U.S., China, Hong Kong, Israel, Japan and South Korea, and would have been Europe's first drug to treat the neurodegenerative condition rather than its symptoms.
The infusion, given twice a month, removes sticky clumps of protein amyloid beta from the brain, believed to be a hallmark of Alzheimer's disease.
In clinical trials, the drug slowed cognitive decline by 27% in early Alzheimer's patients, compared with a placebo.
In Europe, seven million people live with the disease, according to non-profit Alzheimer's Europe, which was disappointed with the decision.
The EU regulator said it relied on the analysis by the agency's Committee for Medicinal Products for Human Use, and cited three primary concerns.
An 18-point scale used in the trial to measure functions such as memory and problem-solving showed only a small absolute difference in patients who received lecanemab versus a placebo, it said.
It also pointed to cases of ARIA, a type of brain swelling and bleeding, seen in its clinical trials that led to hospitalizations of some patients.
The committee noted elevated risk of brain swelling and bleeding in people who have two copies of the APOE4 gene, which is also associated with a higher risk of Alzheimer's.
SCRUTINY IN EUROPE
Reuters reported last year, citing researchers, that the drug was unlikely to be used widely even if approved in Europe, where cost-conscious countries rigorously scrutinize new drugs.
Leqembi's U.S. launch has been lackluster, with bottlenecks due to its requirements such as additional diagnostic tests, twice-monthly infusions and regular brain scans.
One Alzheimer's expert said the decision reflected the complex considerations around the drug, which costs roughly $26,500 per year in the U.S.
The requirements "lead to the question if limited resources (not just money but also trained staff) could produce better results for patients if used elsewhere," said Sebastian Walsh, NIHR Doctoral Fellow, University of Cambridge.
The decision puts pressure on European regulators to create clear guidance on what is the clinically meaningful benefit for treating Alzheimer's disease, said Ivan Koychev, principal clinical investigator at the United Kingdom Dementia Platform.
The recommendation must be backed by the European Commission, which usually follows the regulator's decision.
The drug has been under review in the region since January 2023. The U.S. approved it last year and requires a warning against brain-related side effects.
Lilly's amyloid-lowering drug Kisunla, also known as donanemab, gained U.S. approval this year and is being reviewed by European regulators.
Given the Leqembi rejection, "we are hard-pressed to see the EU approving Lilly's donanemab," Piper Sandler analyst Christopher Raymond said in a research note on Friday.
Officials at Lilly declined to comment on the EU decision, but John Sims, Lilly's senior medical director, told Reuters that the company believes in the favorable benefit-risk profile for amyloid-targeting therapies.
Who can get the newly approved Eisai and Biogen Alzheimer's drug? https://www.reuters.com/business/healthcare-pharmaceuticals/who-can-get-newly-approved-eisai-biogen-alzheimers-drug-2023-01-06/
European Alzheimer's experts unconvinced by new Eisai, Biogen drug https://www.reuters.com/business/healthcare-pharmaceuticals/european-alzheimers-experts-unconvinced-by-new-eisai-biogen-drug-2023-06-13/
Reporting by Manas Mishra and Puyaan Singh in Bengaluru; Deena Beasley in Los Angeles; Editing by Mrigank Dhaniwala, Josephine Mason, Arun Koyyur and Rod Nickel
Aset Berkaitan
Berita Terkini
Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.
Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.
Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.
